{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:11:32Z","timestamp":1791645092323,"version":"4.3.4"},"reference-count":36,"publisher":"American Society of Hematology","issue":"14","license":[{"start":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T00:00:00Z","timestamp":1641513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/legalcode"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,4,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Measurable residual disease (MRD) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy is predictive of early relapse and poor survival. Postremission maintenance therapy that prolongs MRD negativity or converts MRD+ patients to MRD\u2212 status may delay or prevent relapse and improve overall survival (OS). In the phase 3 QUAZAR AML-001 trial, oral azacitidine (oral-AZA; formerly CC-486), a hypomethylating agent, significantly prolonged OS and relapse-free survival (RFS) compared with placebo in patients aged \u226555 years with AML in first remission after intensive chemotherapy who were not candidates for hematopoietic stem cell transplantation. In this trial, MRD (\u22650.1% leukemic cells in bone marrow) was assessed by multiparameter flow cytometry in serial samples collected at baseline and on day 1 of every 3 cycles. As expected, baseline MRD status was significantly associated with both OS and RFS. Multivariate analyses showed oral-AZA significantly improved OS and RFS vs placebo independent of baseline MRD status. Oral-AZA treatment also extended the duration of MRD negativity by 6 months vs placebo and resulted in a higher rate of conversion from MRD+ at baseline to MRD\u2212 during treatment: 37% vs 19%, respectively. In the oral-AZA arm, 24% of MRD responders achieved MRD negativity &amp;gt;6 months after treatment initiation. Although presence or absence of MRD was a strong prognostic indicator of OS and RFS, there were added survival benefits with oral-AZA maintenance therapy compared with placebo, independent of patients\u2019 MRD status at baseline. Registered at clinicaltrials.gov as #NCT01757535.<\/jats:p>","DOI":"10.1182\/blood.2021013404","type":"journal-article","created":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T21:01:11Z","timestamp":1641589271000},"page":"2145-2155","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":66,"title":["Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease status"],"prefix":"10.1182","volume":"139","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0384-3658","authenticated-orcid":false,"given":"Gail J.","family":"Roboz","sequence":"first","affiliation":[{"name":"Weill Cornell Medicine, New York, NY;"},{"name":"New York Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia;"},{"name":"Australian Centre for Blood Diseases, Monash University, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5454-6768","authenticated-orcid":false,"given":"Herv\u00e9","family":"Dombret","sequence":"additional","affiliation":[{"name":"Hematology, H\u00f4pital Saint-Louis, Assistance Publique \u2013 H\u00f4pitaux de Paris (AP-HP), Paris, France;"},{"name":"Institut de Recherche Saint-Louis, Universit\u00e9 de Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[{"name":"Medizinische Hochschule Hannover, Hannover, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6164-4761","authenticated-orcid":false,"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre C.","family":"Schuh","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4112-5902","authenticated-orcid":false,"given":"Kimmo","family":"Porkka","sequence":"additional","affiliation":[{"name":"Hospital District of Helsinki and Uusimaa (HUS) Comprehensive Cancer Center, Hematology Research Unit Helsinki and iCAN Digital Precision Cancer Center Medicine Flagship, University of Helsinki, Finland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignazia","family":"La Torre","sequence":"additional","affiliation":[{"name":"Celgene, a Bristol Myers Squibb Company, Boudry, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Skikne","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, BMS, Princeton, NJ;"},{"name":"Bristol Myers Squibb, University of Kansas Medical Center, Kansas City, KS;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Zhong","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, BMS, Princeton, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. L.","family":"Beach","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, BMS, Princeton, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Risue\u00f1o","sequence":"additional","affiliation":[{"name":"BMS Center for Innovation and Translational Research Europe (CITRE, a Bristol Myers Squibb Company), Seville, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel L.","family":"Menezes","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapeutics, BMS, Princeton, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"Amsterdam UMC, Location VUMC (Vrije Universiteit Medical Center), Amsterdam, The Netherlands; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2022050218130959400_B1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med."},{"issue":"1","key":"2022050218130959400_B2","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1182\/blood-2005-10-4073","article-title":"Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial","volume":"108","author":"Brune","year":"2006","journal-title":"Blood."},{"issue":"13","key":"2022050218130959400_B3","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1182\/blood-2018-10-879866","article-title":"Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients","volume":"133","author":"Huls","year":"2019","journal-title":"Blood."},{"issue":"11","key":"2022050218130959400_B4","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1038\/leu.2012.153","article-title":"A randomized study of decitabine versus conventional care for maintenance therapy in patients with acute myeloid leukemia in complete remission","volume":"26","author":"Boumber","year":"2012","journal-title":"Leukemia."},{"issue":"3","key":"2022050218130959400_B5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1600-0609.1991.tb01560.x","article-title":"Value of maintenance therapy with chemotherapy or interferon during remission of acute myeloid leukaemia","volume":"47","author":"Palva","year":"1991","journal-title":"Eur J Haematol."},{"issue":"5","key":"2022050218130959400_B6","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1182\/blood.V98.5.1302","article-title":"Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial","volume":"98","author":"Goldstone","year":"2001","journal-title":"Blood."},{"issue":"26","key":"2022050218130959400_B7","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1182\/blood-2011-02-337725","article-title":"Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia","volume":"117","author":"Buyse","year":"2011","journal-title":"Blood."},{"issue":"1","key":"2022050218130959400_B8","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2016.252","article-title":"Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)","volume":"31","author":"Blum","year":"2017","journal-title":"Leukemia."},{"issue":"3","key":"2022050218130959400_B9","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1200\/JCO.1998.16.3.872","article-title":"Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy\u2013the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report","volume":"16","author":"L\u00f6wenberg","year":"1998","journal-title":"J Clin Oncol."},{"issue":"10","key":"2022050218130959400_B10","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.3346\/jkms.2015.30.10.1416","article-title":"Oral maintenance chemotherapy with 6-mercaptopurine and methotrexate in patients with acute myeloid leukemia ineligible for transplantation","volume":"30","author":"Choi","year":"2015","journal-title":"J Korean Med Sci."},{"issue":"4","key":"2022050218130959400_B11","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1200\/JCO.2016.67.6213","article-title":"Addition of androgens improves survival in elderly patients with acute myeloid leukemia: a GOELAMS study","volume":"35","author":"Pigneux","year":"2017","journal-title":"J Clin Oncol."},{"issue":"8","key":"2022050218130959400_B12","doi-asserted-by":"crossref","first-page":"e0135520","DOI":"10.1371\/journal.pone.0135520","article-title":"Pharmacokinetics and pharmacodynamics with extended dosing of CC-486 in patients with hematologic malignancies","volume":"10","author":"Laille","year":"2015","journal-title":"PLoS One."},{"issue":"10","key":"2022050218130959400_B13","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/ajh.25216","article-title":"Extended dosing with CC-486 (oral azacitidine) in patients with myeloid malignancies","volume":"93","author":"Savona","year":"2018","journal-title":"Am J Hematol."},{"issue":"18","key":"2022050218130959400_B14","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol."},{"issue":"3","key":"2022050218130959400_B15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/fon.15.326","article-title":"Design of the randomized, phase III, QUAZAR AML maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia","volume":"12","author":"Roboz","year":"2016","journal-title":"Future Oncol."},{"issue":"26","key":"2022050218130959400_B16","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med."},{"issue":"12","key":"2022050218130959400_B17","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.3324\/haematol.2021.279174","article-title":"Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial","volume":"106","author":"Roboz","year":"2021","journal-title":"Haematologica."},{"key":"2022050218130959400_B18","author":"ONUREG (azacitidine tablets) prescribing information"},{"issue":"11","key":"2022050218130959400_B19","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1182\/bloodadvances.2018016378","article-title":"Evaluating measurable residual disease in acute myeloid leukemia","volume":"2","author":"Ravandi","year":"2018","journal-title":"Blood Adv."},{"issue":"4","key":"2022050218130959400_B20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood."},{"issue":"12","key":"2022050218130959400_B21","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1001\/jamaoncol.2020.4600","article-title":"Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia: a systematic review and meta-analysis","volume":"6","author":"Short","year":"2020","journal-title":"JAMA Oncol."},{"issue":"12","key":"2022050218130959400_B22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood."},{"issue":"7","key":"2022050218130959400_B23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ajh.25484","article-title":"Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia","volume":"94","author":"Medeiros","year":"2019","journal-title":"Am J Hematol."},{"issue":"6","key":"2022050218130959400_B24","doi-asserted-by":"crossref","first-page":"721","DOI":"10.6004\/jnccn.2019.0028","article-title":"Acute myeloid leukemia, version 3.2019, NCCN clinical practice guidelines in oncology","volume":"17","author":"Tallman","year":"2019","journal-title":"J Natl Compr Canc Netw."},{"issue":"6","key":"2022050218130959400_B25","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41375-021-01230-4","article-title":"Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations","volume":"35","author":"Walter","year":"2021","journal-title":"Leukemia."},{"issue":"24","key":"2022050218130959400_B26","doi-asserted-by":"crossref","first-page":"6117","DOI":"10.1182\/bloodadvances.2020002811","article-title":"Prognostic impact of complete remission with MRD negativity in patients with relapsed or refractory AML","volume":"4","author":"Short","year":"2020","journal-title":"Blood Adv."},{"key":"2022050218130959400_B27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1182\/blood-2020-137552","article-title":"Molecular predictors and effectiveness of measurable residual disease (MRD) eradication with chemotherapy and allogeneic stem cell transplantation for acute myeloid leukemia","volume":"136","author":"Stahl","year":"2020","journal-title":"Blood."},{"issue":"3","key":"2022050218130959400_B28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.6004\/jnccn.2011.0027","article-title":"Acute myeloid leukemia","volume":"9","author":"O\u2019Donnell","year":"2011","journal-title":"J Natl Compr Canc Netw."},{"issue":"24","key":"2022050218130959400_B29","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol."},{"issue":"6","key":"2022050218130959400_B30","first-page":"646","article-title":"Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow","volume":"88","author":"Kern","year":"2003","journal-title":"Haematologica."},{"issue":"10","key":"2022050218130959400_B31","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1182\/blood-2004-03-1036","article-title":"Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia","volume":"104","author":"Kern","year":"2004","journal-title":"Blood."},{"issue":"1","key":"2022050218130959400_B32","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/10428190600886164","article-title":"Use of five-color staining improves the sensitivity of multiparameter flow cytomeric assessment of minimal residual disease in patients with acute myeloid leukemia","volume":"48","author":"Voskova","year":"2007","journal-title":"Leuk Lymphoma."},{"issue":"12","key":"2022050218130959400_B33","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","article-title":"Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial","volume":"19","author":"Platzbecker","year":"2018","journal-title":"Lancet Oncol."},{"issue":"13","key":"2022050218130959400_B34","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"2022050218130959400_B35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/cyto.b.21968","article-title":"Normal or reactive minor cell populations in bone marrow and peripheral blood mimic minimal residual leukemia by flow cytometry","volume":"100","author":"Li","year":"2021","journal-title":"Cytom B Clin Cytom."},{"key":"2022050218130959400_B36","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2020-134349","article-title":"Impact of measurable residual disease (MRD) by multiparameter flow cytometry (MFC): a real-world study in 1,076 patients with acute myeloid leukemia (AML)","volume":"136","author":"Paiva","year":"2020","journal-title":"Blood."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/14\/2145\/1889594\/bloodbld2021013404.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/139\/14\/2145\/1889594\/bloodbld2021013404.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,22]],"date-time":"2023-01-22T08:03:04Z","timestamp":1674374584000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/139\/14\/2145\/483370\/Oral-azacitidine-prolongs-survival-of-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,7]]},"references-count":36,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2022,4,7]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2021013404","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,7]]}}}